FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 217 filers reported holding FATE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.68 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $784,000 | -36.1% | 31,652 | 0.0% | 0.03% | -27.9% |
| Q1 2022 | $1,227,000 | -71.2% | 31,652 | -56.5% | 0.04% | -68.6% |
| Q4 2021 | $4,255,000 | -1.3% | 72,727 | 0.0% | 0.14% | -1.4% |
| Q3 2021 | $4,311,000 | -31.7% | 72,727 | 0.0% | 0.14% | -32.2% |
| Q2 2021 | $6,312,000 | -49.1% | 72,727 | -51.6% | 0.20% | -51.9% |
| Q1 2021 | $12,396,000 | -18.0% | 150,343 | -9.6% | 0.43% | -19.8% |
| Q4 2020 | $15,123,000 | +74.0% | 166,317 | -23.5% | 0.53% | +62.9% |
| Q3 2020 | $8,692,000 | +36.5% | 217,462 | +17.1% | 0.33% | +34.7% |
| Q2 2020 | $6,370,000 | +73.1% | 185,672 | +12.1% | 0.24% | +45.8% |
| Q1 2020 | $3,680,000 | +13.5% | 165,672 | 0.0% | 0.17% | +35.0% |
| Q4 2019 | $3,242,000 | +26.0% | 165,672 | 0.0% | 0.12% | +9.8% |
| Q3 2019 | $2,573,000 | +419.8% | 165,672 | +579.6% | 0.11% | +460.0% |
| Q2 2019 | $495,000 | – | 24,379 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |